secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001799191-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives
--------------------------------------------------------------------------------

- Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).
- Gross profit $13M (-13.9%); gross margin 13.2% vs 18.8%; adjusted EBITDA ($8.7M) vs ($6.9M).
- Dispensary segment revenue up 76% YoY; 10 capitation contracts signed in 2024 so far.
- Company exploring strategic alternatives to maximize shareholder value.
- Cash $46.4M; full year 2024 guidance updated, expecting H2 improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/0001799191-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/toi-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001799191-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer